BR9713105A - Uso para os derivados de 1,3 - propanodiol - Google Patents

Uso para os derivados de 1,3 - propanodiol

Info

Publication number
BR9713105A
BR9713105A BR9713105-9A BR9713105A BR9713105A BR 9713105 A BR9713105 A BR 9713105A BR 9713105 A BR9713105 A BR 9713105A BR 9713105 A BR9713105 A BR 9713105A
Authority
BR
Brazil
Prior art keywords
prevention
optionally substituted
organ
tissue
derivatives
Prior art date
Application number
BR9713105-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Sylvain Cottens
Robert Paul Hof
Roland Wenger
Original Assignee
Novartis Ag Novartis Sa Movart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag Novartis Sa Movart filed Critical Novartis Ag Novartis Sa Movart
Publication of BR9713105A publication Critical patent/BR9713105A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Receiving Elements (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Peptides Or Proteins (AREA)
BR9713105-9A 1996-11-19 1997-11-17 Uso para os derivados de 1,3 - propanodiol BR9713105A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Publications (1)

Publication Number Publication Date
BR9713105A true BR9713105A (pt) 2000-04-11

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713105-9A BR9713105A (pt) 1996-11-19 1997-11-17 Uso para os derivados de 1,3 - propanodiol

Country Status (24)

Country Link
US (3) US6274629B1 (cg-RX-API-DMAC10.html)
EP (2) EP1312359B1 (cg-RX-API-DMAC10.html)
JP (2) JP4004070B2 (cg-RX-API-DMAC10.html)
CN (2) CN1146411C (cg-RX-API-DMAC10.html)
AT (2) ATE275947T1 (cg-RX-API-DMAC10.html)
AU (1) AU728420B2 (cg-RX-API-DMAC10.html)
BR (1) BR9713105A (cg-RX-API-DMAC10.html)
CA (1) CA2270952C (cg-RX-API-DMAC10.html)
CZ (1) CZ174999A3 (cg-RX-API-DMAC10.html)
DE (2) DE69730727T2 (cg-RX-API-DMAC10.html)
DK (1) DK1312359T3 (cg-RX-API-DMAC10.html)
ES (2) ES2227726T3 (cg-RX-API-DMAC10.html)
GB (1) GB9624038D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0000343A3 (cg-RX-API-DMAC10.html)
ID (1) ID21568A (cg-RX-API-DMAC10.html)
IL (1) IL129824A (cg-RX-API-DMAC10.html)
NO (1) NO992259L (cg-RX-API-DMAC10.html)
NZ (1) NZ335629A (cg-RX-API-DMAC10.html)
PL (1) PL190348B1 (cg-RX-API-DMAC10.html)
PT (2) PT1312359E (cg-RX-API-DMAC10.html)
RU (1) RU2217136C2 (cg-RX-API-DMAC10.html)
SI (1) SI1312359T1 (cg-RX-API-DMAC10.html)
SK (1) SK284806B6 (cg-RX-API-DMAC10.html)
WO (1) WO1998022100A2 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027798A1 (en) 1998-11-11 2000-05-18 Novartis Ag Production of 2-amino-2-[2-(4-c2-20-alkyl-phenyl)ethyl]propane-1,3-diols
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP4318921B2 (ja) * 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
JP4588979B2 (ja) * 2001-04-20 2010-12-01 オプタルモファーマ アクチェンゲゼルシャフト プロドラッグとして使用されうる修飾型シクロスポリン及びその使用
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
MXPA04006709A (es) 2002-01-11 2004-10-04 Sankyo Co Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen.
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2707750A1 (en) 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7838562B2 (en) * 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
AU2014224237B2 (en) * 2013-03-05 2017-07-20 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US20180250235A1 (en) 2015-09-18 2018-09-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
NZ243706A (en) * 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin

Also Published As

Publication number Publication date
NO992259D0 (no) 1999-05-10
ID21568A (id) 1999-06-24
SK284806B6 (sk) 2005-11-03
CZ174999A3 (cs) 1999-08-11
HK1022639A1 (en) 2000-08-18
WO1998022100A3 (en) 1998-06-25
CA2270952C (en) 2007-09-18
IL129824A0 (en) 2000-02-29
GB9624038D0 (en) 1997-01-08
EP1312359A3 (en) 2004-01-02
CA2270952A1 (en) 1998-05-28
EP0941082A2 (en) 1999-09-15
CN1146411C (zh) 2004-04-21
EP1312359B1 (en) 2007-08-15
JP4004070B2 (ja) 2007-11-07
PT941082E (pt) 2004-12-31
DE69730727T2 (de) 2005-09-22
PL190348B1 (pl) 2005-11-30
NO992259L (no) 1999-05-10
HUP0000343A3 (en) 2001-06-28
WO1998022100A2 (en) 1998-05-28
PT1312359E (pt) 2007-11-09
CN1293876C (zh) 2007-01-10
IL129824A (en) 2003-07-31
ES2289041T3 (es) 2008-02-01
SK65999A3 (en) 1999-12-10
DE69738033D1 (de) 2007-09-27
US20010056124A1 (en) 2001-12-27
PL333463A1 (en) 1999-12-20
DE69738033T2 (de) 2008-04-30
CN1515253A (zh) 2004-07-28
ES2227726T3 (es) 2005-04-01
EP1312359A2 (en) 2003-05-21
US20030069315A1 (en) 2003-04-10
RU2217136C2 (ru) 2003-11-27
EP0941082B1 (en) 2004-09-15
US6486209B2 (en) 2002-11-26
DK1312359T3 (da) 2007-10-08
ATE275947T1 (de) 2004-10-15
US6274629B1 (en) 2001-08-14
HUP0000343A2 (hu) 2000-12-28
AU728420B2 (en) 2001-01-11
DE69730727D1 (de) 2004-10-21
CN1237906A (zh) 1999-12-08
NZ335629A (en) 2001-09-28
ATE369846T1 (de) 2007-09-15
JP2001503780A (ja) 2001-03-21
JP2004256554A (ja) 2004-09-16
SI1312359T1 (sl) 2008-08-31
AU5483198A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
BR9811933A (pt) Vinil éteres heterocìclicos contra distúrbios neurológicos
WO1998022100A3 (en) New use for 1,3-propanediol derivatives
BR9913952A (pt) Quimioterapia de câncer com acetildinalina em combinação com gemcitabina, capecitabina ou cisplatina
BR9815200A (pt) Composto, composição farmacêutica e método de tratamento de uma doença ou distúrbio mediado pela inibição de cdk4 ou um complexo de cdk4/ciclina
BR0109867A (pt) 2-guanidino-4-arilquinazolinas como inibidores de nhe-3
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
ATE252572T1 (de) 5-ht1f agonisten
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
ATE297945T1 (de) Glutathionderivate und dazugehörige dosisformen
BR0115949A (pt) Composição oral aquosa, estável, contendo zinco, tendo baixa adstringência, e, método para preparar a mesma
BR0015487A (pt) Compostos de imidazol como inibidores de fosfodiesterase vii
DK0640080T3 (da) Substituerede indoler som angiotensin II antagonister
BR0010802A (pt) Antagonistas de receptor il-8
BR9808803A (pt) Derivado de 20-aralquil-5alfa-pregnano, uso do mesmo, e, composição farmacêutica
BR0008321A (pt) Secretagogos de hormÈnio de crescimento
BR9915879A (pt) Antagonista de receptor de vitronectina
MX11866A (es) Nuevas cicloalquilamidas y procedimiento para su preparacion.
BR9916188A (pt) Derivados de cromano
IT1298965B1 (it) Derivati dell'indolo atti all'impiego come composti cromogeni
EA200100918A1 (ru) Агонисты 5-ht1f рецептора
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
ES509554A0 (es) "procedimiento para la preparacion de nuevas cefalosporinas".
YU43499A (sh) Kristalna hidratovana natrijumova so (e)-4,6-dihloro-3- (2-okso-1-fenilpirolidin-3-iliden metil)-1h-indol-2- karboksilne kiseline
ES510739A0 (es) "procedimiento para la preparacion de 1,1-dioxidos de 4-hidroxi-1,2-benzoisotiazol-3(2h)-ona".

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/137, A61K 31/13, A61K 31/133, A61K 31/135, A61P 37/06, A61P 37/02

Ipc: A61K 31/137 (2007.10), A61K 31/13 (2007.10), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11, E 13 DALPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]